Arkin Capital has launched a new $100 million biotech fund.
Instead of following the popular trend of using artificial intelligence to discover new medicines, the company is continuing with its own traditional biotech investment strategy.
The fund, called Arkin Bio Ventures III, will invest in early-stage biotech companies that are working on new medicines.
It will focus on serious health areas where better treatments are urgently needed, such as cancer, immune system diseases, inflammation, and rare diseases.
The fund is supported by big investors like Phoenix Insurance, Clal Insurance, and Amitim Pension Funds, and Arkin Capital has also invested a large amount of its own money.
Even though many companies are now using AI and computer tools to discover new drugs, Arkin is following a more traditional method.
The firm believes that successful medicines should be developed using strong biological research, careful testing, and reliable clinical trial results.
This new fund continues the same strategy used in Arkin’s earlier funds launched in 2016 and 2020.
However, it puts more focus on companies that are already closer to clinical testing and approval.
“Our commitment is to frontline science and the teams bringing it to life,” said Dr Orbach, managing partner at Arkin Bio. The new fund, he said, is designed to push promising private companies toward clinical proof-of-concept by combining scientific rigor with investment discipline and a global network.
Read More- NEOM Chooses Five Saudi Studios for Level Up Accelerator
